The first shelter hospital in Wuhan of "medical fast reading society" begins to accept patients, mosadong and GSK will be split

24:00, Feb 5: more than 28000 cases have been confirmed nationwide; Wuhan's first shelter hospital has begun to accept patients; Wuhan's 30 hour newborn diagnosis experts say or save mother to child vertical transmission; another multinational pharmaceutical company will be split up after MSD; Novo Nordisk 2019 financial report announced: China's revenue of 13.2 billion yuan As of 24:00 on February 5, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps have reported 28018 confirmed cases, 1153 cured and discharged cases, 26302 isolated cases (3859 severe cases), 563 dead cases and 24702 suspected cases There were 282813 close contacts and 186354 close contacts still under medical observation (official website of National Health Commission) On May 5, medical staff were in Jianghan fangcang hospital Novel coronavirus was launched in Wuhan International Convention and Exhibition Center in Jianghan District at 22 o'clock, and began receiving new pneumonia caused by coronavirus infection in Wuhan This "shelter hospital" is called Jianghan shelter hospital, with 1600 beds (Xinhua News Agency) WHO announced novel coronavirus epidemic strategy at the headquarters of Geneva 5, to provide guidance for formulating the epidemic response plan at different countries or regions (Xinhua News Agency) Novel coronavirus pneumonia was diagnosed in two neonates in the hospital from 5 children's Hospital, Wuhan The youngest confirmed child was born only 30 hours It should be paid more attention to that there may be a mother infant vertical infection transmission pathway considered by experts of neonatal medicine in Wuhan children's hospital At present, the vital signs of all newborns in the area are stable, and there are no critical cases The team of experts will closely observe the newborn cases and provide perfect monitoring and treatment (people's daily) On the 5th, MSD announced that it would spin off its women's health products, mature products and bio generic products and set up a new independent listed company "Newco"; on the same day, GSK, another multinational pharmaceutical company, also announced its split plan: divide the company into two entities in the next two years: one will focus on drugs and drug development, the other will focus on consumer healthcare products (Sina Medical News) On May 5, Novo Nordisk announced its 2019 results, with a total annual revenue of DKK 122 billion 21 million (about US $18 billion 294 million), an increase of 9% year-on-year Among them, the revenue of DKK 12.844 billion (about 13.241 billion yuan) in China increased by 14% year-on-year, which is the second growth area in nordnode's business division, next to aameo (medicine cube) In February last year, mylan launched a patent challenge to Bogen for the multiple sclerosis drug tecfidera In this week's ruling, the patent judge ruled that the evidence available was insufficient to support mylan's challenge of certain patents for the drug This means that Bojian can continue to defend tecfidera from copying (Sina Medical News) Today, Maat Pharma, headquartered in Lyon, France, announced the completion of the EUR 18 million (US $20 million) round B financing to promote the further clinical development of its microbiome candidate drugs for the treatment of blood cancer and expand it to the treatment of other solid tumor indications (chuangjianhui) On May 5, with the support of the Ministry of science and technology, the national health and Health Commission, the State Food and Drug Administration and other departments, the antiviral drug remdesivir has completed the registration and approval of clinical trials, and the first batch of cases have been put in place The first novel coronavirus infected severe pneumonia patients will receive medication in February 6th (Xinhua News Agency) Recently, Lilly and Incyte announced that the primary end point of the phase III clinical study breeze-ad5 for the evaluation of oral JAK inhibitor olumiant (barictinib) in the treatment of adult patients with moderate to severe atopic dermatitis has been reached (Biovalley) On the 5th, AstraZeneca's selumetinib capsule obtained the tacit clinical permission for the treatment of symptomatic and / or progressive neurofibromatosis type I (NF1) - related plexiform neurofibroma (PN) in children and adolescents aged 3 and over (medicine cube) China's first cefdinir dispersible tablet (0.1g), a stock holding subsidiary of Sinopharm Zhijun, passed the consistency evaluation Thursday, Hyundai pharmaceutical announced (modern pharmaceutical announcement)